[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624070":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":62,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment - Stimulation with Transcutaneous Auricular Vagal Nerve Stimulator","EXPERIMENTAL","All patients will be fitted with the device, the investigator will attach an electrode to the left ear. Stimulation sessions will occur for 20 minutes twice daily during the inpatient period, the investigator will stimulate the auricular branch of the vagus nerve. Patients' will be treated with the following parameters: frequency 20 Hz, pulse width 250 μm, and and a fixed intensity of 0.5 milliampere.",[13],"Device: transcutaneous auricular vagal nerve stimulation",{"label":15,"type":16,"description":17,"interventionNames":18},"Control - No Stimulation Transcutaneous Auricular Vagal Nerve Stimulator","SHAM_COMPARATOR","All patients will be fitted with the device, the investigator will attach an electrode to the left ear. Sham stimulation sessions will occur for 20 minutes twice daily during the inpatient period. Patients assigned to the controls arm will have no electricity applied to the auricular branch of the vagus nerve.",[19],"Device: Sham transcutaneous vagal nerve stimulation",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","transcutaneous auricular vagal nerve stimulation","Stimulus of the auricular branch of the vagal nerve with the transcutaneous auricular vagal nerve stimulation.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Sham transcutaneous vagal nerve stimulation","Patients assigned to the controls arm will have no electricity applied to the Auricular Branch of the Vagus Nerve.",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Angela Birke, MS","CONTACT","(314) 362-5291","birkea@wustl.edu",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Osvaldo Laurido-Soto, MD","314-273-3294","ojlaurido-soto@wustl.edu",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Barnes-Jewish Hospital","RECRUITING","St Louis","Missouri","63110","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-90.19789,38.62727,{"lat":54,"lon":53},[57,58,60],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"name":59,"role":34,"phone":26,"phoneExt":26,"email":40},"Osvaldo J Laurido-Soto, MD",{"name":59,"role":61,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":61,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Osvaldo J. Laurido-Soto, MD","Assistant Professor of Neurology","100624070","non-invasive-vagus-nerve-stimulation-to-reduce-inflammation-and-brain-injury-blood-biomarkers-following-an-acute-ischemic-stroke-100624070",false,"NCT07404852","Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemic Stroke","Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct 2","NUVISTA2","Inclusion Criteria:\n\n* Adult patients who present with acute ischemic strokes due to large vessel occlusions\n\nExclusion Criteria:\n\n* \\\u003C18 years old\n* patients with presumed chronic large vessel occlusions\n* NIHSS\\\u003C6\n* pre-morbid modified Rankin score (mRS) \\>2\n* unable to initiate treatment under 24 hours from symptom discovery\n* Chronic or acute infection, Recent surgery, active immune disease\n* life expectancy \\\u003C3 months\n* patients' undergoing active cancer or immunosuppressive\u002Fmodulating therapy\n* patients with sustained bradycardia on arrival with a heart rate \\\u003C50 beats per minute.","ALL","18 Years","99 Years",{"count":77,"type":78},65,"ESTIMATED","INTERVENTIONAL",[81],"NA","This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory and brain injury laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions and are treated with either current accepted management, or accepted management in addition to transcutaneous auricular vagal nerve stimulation.",[84,85],"Large Vessel Occlusion","Acute Ischemic Stroke",[87,88,89,90,91],"Acute ischemic stroke","large vessel occlusion","cytokines","vagus nerve stimulator","brain injury biomarkers","2026-04-08",{"date":94,"type":95},"2026-04-13","ACTUAL",{"date":97,"type":95},"2026-02-23",{"date":99,"type":78},"2028-02-29",{"name":5,"class":6},1]